Current status of outcome measures in vasculitis: Focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7

Journal of Rheumatology

Volumn 32, Issue 12, 2005, Pages 2488-2495

  Merkel, Peter A ^a   Seo, Philip ^b   Aries, Peter ^c   Neogi, Tuhina ^a   Villa Forte, Alexandra ^d   Boers, Maarten ^e   Cuthbertson, David ^e   Felson, David T ^a   Hellmich, Bernhard ^b   Hoffman, Gary S ^d   Jayne, David R ^f   Kallenberg, Cees G M ^j   Krischer, Jeffrey ^g   Mahr, Alfred ^h   Matteson, Eric L ⁱ   Specks, Ulrich ⁱ   Luqmani, Raashid ^a   Stone, John H ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c University of Schleswig Holstein   (Germany)

^d LERNER RESEARCH INSTITUTE   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h Hôpital Cochin ^*  (France)

ⁱ Mayo Clinic   (United States)

^j Boston University School of Medicine ^*

more..

Author keywords

Microscopic polyangiitis; Outcome measures; Vasculitis; Wegener's granulomatosis

Indexed keywords

ANCA ASSOCIATED VASCULITIS; CHRONIC DISEASE; CLINICAL RESEARCH; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULITIS; WEGENER GRANULOMATOSIS;

CLINICAL TRIALS; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 23644432864     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-8.
2. Stone JH, Huffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001;44:912-20.
3. Whiting-O'Keefe QE, Stone JH, Hellmann DB. Validity of a vasculitis activity index for systemic necrotizing vasculitis. Arthritis Rheum 1999;42:2365-71.
4. de Groot K, Gross WL, Herlyn K, Reinhold-Keller E. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-8.
5. Exley AR, Bacon PA, Luqmani RA, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997;40:371-80.
6. Kallenberg CG, Tervaert JW, Stegeman CA. Criteria for disease activity in Wegener's granulomatosis: a requirement for longitudinal clinical studies. APMIS Suppl 1990;19:37-9.
7. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome, A prospective study in 342 patients. Medicine Baltimore 1996;75:17-28.
8. Savage CO. Microscopic polyarteritis: definition and relation to Wegener's granulomatosis. APMIS Suppl 1989;6:8-9.
9. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic potyangiitis and glomerulonephritis. J Am Soc Nephrol 1996;7:33-9.
10. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-37.
11. Hunder GG, Arend WP, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990;33:1065-7.
12. Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 1990;33:1135-6.
13. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitis, proposal of an international conference. Arthritis Rheum 1994;37:187-92.
14. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003;114:463-9.
15. de Groot K, Schmidt DK, Arlt AC, Gross WL, Reinhold-Keller E. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001;58:1215-21.
16. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
17. WGET Research Group. Design of the Wegener's granulomatosis etanercept trial (WGET). Control Clin Trials 2002;23:450-68.
18. Carrington CB, Liebow A. Limited forms of angiitis and granulomatosis of Wegener's type. Am J Med 1966;41:497-527.
19. Jayne D. Update on the European Vasculitis Study Group trials. Curr Opin Rheumatol 2001;13:48-55.
20. WGET Research Group. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003;48:2299-309.
21. Exley AR, Carruthers DM, Luqmani RA, et al. Damage occurs early in systemic vasculitis and is an index of outcome. Q J Med 1997;90:391-9.
22. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index. Br J Rheumatol 1998;37:57-63.
23. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998;25:198-9.